Pharmafile Logo
T40 2022 Cover
Diversity, Equity and Inclusion
Communiqué 53 Cover Image
- PMLiVE

Specialty Medicine

- PMLiVE

Bayer gets new Japanese approval for Stivarga

Additional licence covers drug's use in gastrointestinal stromal tumours

Novartis building

Novartis drawn into Chinese corruption probe

Former sales rep files bribery complaint about Sandostatin LAR prescribing practices

China flag thumb

China’s bribery probe goes national

Expands investigation that already affects GSK, Sanofi, Lilly, AZ, Lundbeck, Novo and UCB

China flag thumb

Sanofi drawn into Chinese corruption probe

Joins GSK, UCB, AZ , Lilly, Novo and Lundbeck as companies under scrutiny

Bayer symbol

Bayer moves closer to US approval of PAH drug riociguat

FDA panel votes unanimously in favour of hypertension treatment

Bayer symbol

Bayer to research cancer immunotherapies with Compugen

Will develop drugs that boost response of body’s immune system to tumours

China flag thumb

Sanofi and Lilly also visited by Chinese authorities

Follows GSK bribery allegations

- PMLiVE

GSK replaces China head as bribery probe rolls on

Herve Gisserot takes over from Mark Reilly

- PMLiVE

Witty says Chinese bribery probe will impact GSK

CEO says company’s performance in China will be affected

National Institute for Health and Care Excellence NICE logo

NICE gives final backing to drugs from Bayer, GSK and Otsuka

Eylea, Revolade and Abilify all recommended for NHS use

China flag thumb

AstraZeneca and UCB drawn into Chinese investigations

Follows country’s clampdown on GSK bribery

- PMLiVE

GSK concedes execs may have broken Chinese law

President of international operations suggests senior execs were involved in bribery scandal

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links